Assessment of Mexidol's effectiveness in the complex treatment of glaucomone neuropathy

Authors:
A.N. BOLATBEKOVA, D.E. KOPBAEVA, A.I. ARINOVA, B.S. ABRAKHMANOVA

LLP "Center for Eye Microsurgery", Karaganda;
KGP "Regional Clinical Hospital", Karaganda;
Karaganda State Medical University, Karaganda

Place of publication:
OCCUPATIONAL HYGIENE AND MEDICAL ECOLOGY. No. 2 (47), 2015

Abstract:
This article analyzes the results of an open comparative study of the efficacy and safety of Mexidol injection solution as part of therapy in patients with open-angle glaucoma at various stages. The clinical trial confirmed the good tolerability of Mexidol injection solution when administered to patients with various stages of open-angle glaucoma at doses of 100–300 mg/day intramuscularly for 14–21 days. It is proposed to include Mexidol, a pathogenetically targeted drug with a multifaceted effect, in the combination therapy of patients with POAG at various stages. The identified adverse events associated with this therapy are considered minor, and their likelihood is included in the instructions for medical use of the study drugs. Due to its membrane-protective, nootropic, antihypoxic and antioxidant effects, Mexidol is recommended for use in the complex treatment of glaucomatous optic neuropathy in both the early and late stages of the disease.